Head. Thank you. Operator, welcome to the presentation of the Bactiguard Q3 2024 report. I will go through the presentation together with my colleague Patrick Bach, our CFO, and open up for questions towards the end. Thank you all for dialing in today. Let's go straight into the overarching theme of the report. We are very pleased to announce profitability on an EBITDA level, both for the third quarter and year to date. This is a demonstration that our licensed, focused strategy and business model, which we embarked on late last year, is working and effective. As you know, we also had some disappointing news in early October after the end of the quarter when Zimmer Biomet terminated the agreement covering multiple orthopedic product segments. The broad commercial potential in these segments was a key driver of our 2020 financial targets. Considering this, and to further seize the opportunity for reflection after last year's transformation work, we have decided to initiate a review of our financial targets. The outcome will be communicated in Q1 2025.
Importantly, our partnership with Zimmer Biomet within the trauma segment remains in effect, and I will return to the Zimmer partnership later in the presentation. I wanted to give some brief overall comments on the financial development of the third quarter, and as usual, Patrick will review these in more detail later in the presentation. Our total revenues for Q3 amounted to 73.9 million SEK, an increase of almost 50% compared to the same period last year. We report a positive EBITDA of 9.9 million SEK for the third quarter, which means that we have become profitable on an EBITDA level, not just for the quarter, but also year to date. The profitability was delivered from a combination of increased revenues, where solid growth within the BD partnership was the main driver, as well as a disciplined approach to costs. Another highlight of the quarter was the strong performance of the Wound Management portfolio. Overall, while we are humble about the challenges ahead and acknowledge that we still have much to do, we remain committed to delivering EBITDA profitability for 2020. For a quick recap of what Bactiguard does. Our unique infection prevention technology is an ultra-thin coating of the noble metals gold, silver, and palladium. We license the technology to global medtech companies and develop a different coating process for each medical device. The total quantities of the noble metals on any given device, however, are minimal. But when in contact with fluids, the galvanic effect creates something akin to an electric fence, resulting in the inhibition of microbe adherence to the surface of the devices. In the pictures in the lower right of the slide taken with an electron microscope, you can see the difference in bacterial colonization between an uncoated surface on the left and a Bactiguard-coated surface on the right. The Bactiguard side shows significantly fewer bacteria colonizing, which reduces biofilm formation over time and leads to lowered rates of infection over the years. A wealth of data has been amassed, all pointing to the effectiveness of our technology. More than 100,000 patients have been part of over 40 clinical trials covering case reports to randomized controlled trials, and the results have been published in renowned peer-reviewed publications. Our studies cover various patient cohorts, continents, and regions, and different therapeutic areas. In short, we know our technology works. The need for infection prevention is increasing due to the challenges in delivering effective healthcare globally. Sepsis, which I mentioned in my CEO statement, is merely one example of the importance of prevention. 50 million people contract sepsis when an infection goes astray, and more than 11 million die each year. In addition, the demand for more effective and safe healthcare solutions is driven by economic and demographic developments, increased political unrest, conflicts, wars, and natural disasters.
There are many unmet medical needs that arise from these pressing global societal challenges, including sepsis, healthcare-associated infections, and antimicrobial resistance. The medical need also brings commercial opportunities for Bactiguard within our various strategic therapeutic areas. In fact, they drive home our mission to work with leading MedTech companies to enable differentiated medical devices to be brought to the market. We see an increased interest in our infection prevention technology, and I will comment further on that shortly. Wound Management clearly represents a significant market size and growth opportunity, considering the positive Q3 momentum in our Wound Management portfolio. One year has passed since we embarked on the journey towards a sharpened, license-focused strategy around our coating technology, and we have undergone a fundamental shift, going from production and sales to becoming a knowledge specialist and licensed partnership organization. Reaching EBITDA profitability for 2024 already in the third quarter serves as excellent evidence that our strategy and business model are effective, and that the transformation is well underway and making progress. Our overarching focus areas remain the same: licensed partnerships, strengthening the knowledge and specialist organization further, and growing our Wound Management portfolio profitably.
I would like to take a deeper dive into the license-related green boxes. Our key priority is working in partnership with leading global MedTech players, and this includes two core parts. Firstly, advancing current partnerships where the positive development of the relationship with BD is a great example, which I will come back to in a few minutes. And secondly, by developing new licensing partnerships. We do this by delivering our competencies into our partnerships to develop processes and IP, demonstrate patient benefit, and enhance our partners' product differentiation. This relationship is a virtuous cycle. The more we understand and educate the market about our technology and its ability to mitigate infection risk, the more interest we see in our technology platform, the stronger our partnerships become, enabling us to continue developing our competencies and so on.
In this context, I would like to revisit our business model, which we introduced in connection with the Q3 report last year.
The green section is clearly the most important from a revenue generation perspective.
Our revenues are generated in three categories: application development, exclusivity fees, and license revenues. Our work to deliver partnerships begins earlier, however, in the beige part of the figure. As I noted before, we are seeing increased interest in our infection prevention technology from global MedTech players, and we are currently exploring the application of our technology across various strategic therapeutic areas. Our R&D team is currently engaged in early-stage testing in collaboration with potential partners across various therapeutic areas. We are testing the performance of our technology on various medical devices, materials, and surfaces. This early stage testing and even full application development projects are best executed in a confidential manner, and we are committed to safeguarding competitive advantages for our partners, particularly at this stage of the partnership journey. Additionally, some application development projects will materialize and some will not. This is a natural part of our business. In accordance with our business model, we are announcing partners once the early stage projects convert into exclusivity and licensed partnerships. We believe this provides a more relevant perspective on when meaningful revenues from the partnerships will commence. Now, let's turn to more on our licensed partnerships. Looking at the quarter in isolation, the solid growth in revenues from BD was the main driver of our positive EBITDA. We have had three stable quarters and now see growth.
Reviewing the collaboration both over the last nine months and through the third quarter, we are extremely pleased with how the partnership has developed. We now have a truly global approach and are working even more closely together on the expansion of Bactiguard-coated Foley catheters into both existing and new markets. Our collaboration has transitioned into a strategic partner cooperation, and Bactiguard now engages with BD across the entire value chain from technology through to market. Here you see a recent photo of the collaboration, with the Bactiguard BD project leader to the left and a BD representative to the right. At the Urology Week event organised by the Swedish Urological Association in Norrköping, Sweden. Importantly, the evolution of the relationship with BD demonstrates how our license-focused strategy is proving effective. It is a global approach in close partnership, and it is growing. BD's success is Bactiguard's success. Returning to Zimmer Biomet, the termination of the agreement covering multiple orthopedic product segments in early October was clearly a disappointment. While Zimmer Biomet are strong believers in the importance of infection prevention and our technology, they informed us that they were not prepared to commit to a more complex and lengthier US FDA pathway than originally anticipated. The agreement for these segments was signed back in 2022. We are now in dialogue with Zimmer Biomet to detail the near-term responsibilities and analyze the longer-term impact of the termination. While the termination was a disappointment, Bactiguard now fully owns the rights and is free to seek additional partnerships within orthopedic segments outside of trauma, where our agreement with Zimmer Biomet does remain in effect. Within the trauma setting, infection rates are significantly higher than, for example, in elective reconstructive procedures, and consequently, the need for infection prevention is more pressing. In the partnership, we are working together on regulatory processes in Europe and the US, and we continue to support the commercialization activities for the Z-n Bactiguard trauma nail, especially in Europe. A highlight in Q3 was the way Zimmer Biomet presented our technology at the European Bone and Joint Infection Society's conference in Barcelona. A trauma implant placed in an interactive glass cylinder illustrated the mode of action. Your finger represented. The microbes touching the cylinder, and the light effect demonstrated the prevention of attachment to the device. Zimmer Biomet also arranged a cool event on infection prevention measures for metal implants, highlighting our technology.
The event in Barcelona is yet another example of the continued commercial collaboration between Bactiguard and Zimmer Biomet within trauma. Here in the final photo are our Zimmer Biomet Alliance manager and our CMO, along with colleagues from Zimmer Biomet. Separate from the technology licensing focus, we continue to grow in the Wound Management portfolio.
The product portfolio had a strong third quarter and continued its trajectory of profitable growth. These pictures are from this past weekend, where we participated in the Global Wound Conference in Selangor, Malaysia, organized by the International Wound Infection Institute. Additionally, a few days ago, the results of a randomized study with Hydrocyn aqua were published in the British Journal of Surgery. The study showed that using Hydrocyn aqua solution in peritoneal and wound lavage reduced overall surgical site infections by 58% and superficial surgical site infections by 72%. These significant results further reinforce the efficacy of Hydrocyn aqua in infection prevention. In addition to Hydrocyn aqua, our wound management portfolio consists of a wide range of surgical sutures, including specialty sutures for cardiovascular and ocular operations. And with that, I will hand over to Patrick Bach, our CFO, to go through our financials in more detail.